Pfizer Covid-19 shot safely bolsters antibodies in kids aged 5 to 11
Pfizer Inc. and partner BioNTech SE said their Covid-19 vaccine was safe and produced strong antibody responses in children ages 5 to 11 in a large-scale trial, findings that could pave the way to begin vaccinating grade-school kids within months. The long-awaited results offer one of the first looks at how well a…